Skip to main content
. 2019 Jun 20;4(12):e125377. doi: 10.1172/jci.insight.125377

Figure 2. Thymic function is significantly reduced in patients treated with palifermin (n = 14) versus placebo (n = 14).

Figure 2

(A) Numbers of circulating naive (CCR7+CD45RA+) CD4+ T cells. (B) Numbers of circulating CD4+ recent thymic emigrants (RTEs), defined as naive CD4+ T cells coexpressing CD31. (C) T cell receptor excision circles (TRECs) per ml of blood, at baseline (0) and months 3 and 6 after alemtuzumab. The data shown are the mean ± SD; P values are shown for the month 6 data and were calculated using Mann-Whitney nonparametric tests. Naive CD4+ cell count at month 6 was the predefined interim primary outcome measure. P values for RTEs and TRECs are shown for descriptive purposes only.